Co-Diagnostics, Inc. (MUN:C970)

Market Cap	19.54M +115.3%
Revenue (ttm)	622.87K -79.5%
Net Income	-42.07M
EPS	-25.87
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8
Open	8.82
Previous Close	10.50
Day's Range	8.82 - 9.96
52-Week Range	8.76 - 32.40
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	May 14, 2026

About Co-Diagnostics

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2013
• Employees: 115
• Stock Exchange: Munich Stock Exchange
• Ticker Symbol: C970

Financial Performance

In 2025, Co-Diagnostics's revenue was $622,489, a decrease of -84.10% compared to the previous year's $3.92 million. Losses were -$46.90 million, 24.6% more than in 2024.

Financial numbers in USD